+173.8%
DAL vs GSK
+63.2%
+110.6%
-47.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.2% | -0.2% | +2.3% | +2.2% |
| 7D | +8.8% | +1.7% | +7.1% | +8.6% |
| 30D | +5.4% | +7.0% | -1.6% | +4.5% |
| 3M | -4.9% | -2.7% | -2.3% | -4.6% |
| 6M | +19.8% | +1.4% | +18.4% | +19.6% |
| YTD | +27.0% | +5.3% | +21.6% | +27.0% |
| 1Y | +52.5% | +10.6% | +41.8% | +52.1% |
| 3Y | +173.8% | +62.6% | +111.3% | +172.4% |
| All | +173.8% | +63.2% | +110.6% | +172.4% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling